Gene therapy recovery drug for $665,000 offered with money back guarantee

Screen Shot at AM

A gene therapy will be offered for sale in Europe with a money-back guarantee, according to GlaxoSmithKline, the company commercializing it.

The treatment, called Strimvelis, is the first outright cure for a rare disorder to emerge from gene therapy, and its price tag of 594,000 euros ($665,000)…makes it one of the most expensive one-time treatments ever sold by a drug firm.

By some measures, Strimvelis’s price counts as a bargain. The cost of a bone marrow transplant from another person…can reach $1 million…The expense of these drugs and the care needed for a sick child quickly add up to millions.


“I was expecting a higher price,” says Christian Hill…“My initial gut feeling was ‘Hmmm, that’s really surprising.’”

But the big question isn’t whether gene therapy costs too much—it’s whether companies can make any money at it, especially treating ultra-rare diseases. Only about a dozen children are born with ADA-SCID each year in Europe. Treating all of them would generate about $8 million in revenue—barely a blip for GSK, which sells $30 billion worth of drugs a year.


The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. Read full, original post: Gene-Therapy Cure Has Money-Back Guarantee

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend